ConductScience.org, home

Trial · NCT04356937

Participant flow12

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Randomization (Safety Population)STARTEDTocilizumab161
Randomization (Safety Population)STARTEDPlacebo82
Randomization (Safety Population)COMPLETEDTocilizumab161
Randomization (Safety Population)COMPLETEDPlacebo82
Randomization (Safety Population)NOT COMPLETEDTocilizumab0
Randomization (Safety Population)NOT COMPLETEDPlacebo0
Treatment (mITT Population)STARTEDTocilizumab161
Treatment (mITT Population)STARTEDPlacebo82
Treatment (mITT Population)COMPLETEDTocilizumab161
Treatment (mITT Population)COMPLETEDPlacebo81
Treatment (mITT Population)NOT COMPLETEDTocilizumab0
Treatment (mITT Population)NOT COMPLETEDPlacebo1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04356937/flow